Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis

Cellenkos® Inc. announced that it has dosed the first patient in a Phase I/Ib study evaluating CK0803 for treatment of amyotrophic lateral sclerosis. CK0803 is a neurotrophic, allogeneic, umbilical cord blood-derived T regulatory cell therapy that preferentially homes towards central nervous system.